08:53 AM EST, 11/21/2025 (MT Newswires) -- (Updates to add Waltz Health's comment in the seventh and eighth paragraphs.)

Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) are set to begin offering their popular GLP-1 medications to employers at fixed prices, avoiding rebates and fees that typically arise with traditional drug sales channels, Bloomberg reported Friday.

Lilly's Zepbound and Novo Nordisk's ( NVO ) Wegovy will be sold to companies through digital health firm Waltz Health starting Jan. 1, the report said.

A number of companies have expressed interest in the offer, with four employer clients ready to launch the offering in January, Reuters reported, citing Waltz Chief Executive Officer Mark Thierer.

The offering is targeted to employers that currently don't offer weight management drugs, the report said.

"Transparent initiatives like these enable more employers to opt in to coverage for authentic, FDA-approved GLP-1medicines while providing people who need care with a seamless experience that allows them to prioritize their health," a Novo Nordisk ( NVO ) spokesperson said in an email to MT Newswires.

Lilly did not immediately reply to a request for comment.

Waltz Health said it will launch a direct-to-employer model on Jan. 1, 2026, giving self-insured employers a new way to cover FDA-approved obesity medicines with fixed pricing, clinical safeguards, and employee support.

Waltz Health said Novo Nordisk ( NVO ) has agreed to participate, and it is also working with Eli Lilly ( LLY ) to broaden access to obesity treatments.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)